Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet (NYSE:ZBH) has strengthened its medical leadership with two key appointments. Dr. Jonathan M. Vigdorchik joins as Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, while Dr. Anand M. Murthi becomes Chief Medical Advisor for Shoulder, Sports, Extremities, and Trauma (S.E.T.).
Both advisors will contribute their clinical expertise to guide product development, enhance medical education initiatives, and serve as strategic liaisons between Zimmer Biomet and the surgical community. Dr. Vigdorchik is from Hospital for Special Surgery in New York City, and Dr. Murthi serves at MedStar Union Memorial Hospital in Baltimore.
Zimmer Biomet (NYSE:ZBH), a global medical technology leader, has announced its quarterly dividend for Q3 2025. The company's Board of Directors approved a cash dividend of $0.24 per share. The dividend will be paid on or around October 31, 2025 to stockholders of record as of the close of business on September 30, 2025.
Zimmer Biomet (NYSE:ZBH) announced its participation in the upcoming Annual Morgan Stanley Healthcare Conference. The company's management team will deliver a presentation on Monday, September 8, 2025, at 8:30 a.m. ET.
Investors can access the live webcast through Zimmer Biomet's Investor Relations website. The presentation will also be available for replay after the conference concludes.
Zimmer Biomet (NYSE:ZBH) reported strong Q2 2025 financial results with net sales of $2.077 billion, up 7.0% year-over-year. The company achieved diluted EPS of $0.77 and adjusted EPS of $2.07, representing a 3.0% increase.
Key highlights include robust growth in U.S. Hips (5.2%) and Knees portfolios, along with significant S.E.T. business growth of 17.3%. The company announced a strategic acquisition of Monogram Technologies to expand its robotics capabilities and formed a partnership with Getinge for Operating Room products distribution.
Zimmer Biomet raised its 2025 guidance, now expecting revenue growth of 6.7-7.7% (reported) and adjusted EPS of $8.10-$8.30, up from previous guidance of $7.90-$8.10.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Monogram Technologies (NASDAQ: MGRM) for an upfront payment of $4.04 per share, representing an equity value of approximately $177 million. The deal includes a CVR worth up to $12.37 per share tied to development milestones through 2030.
The acquisition will expand Zimmer Biomet's ROSA® Robotics platform with Monogram's semi- and fully autonomous robotic technologies. Monogram's FDA-cleared CT-based, semi-autonomous AI-navigated total knee arthroplasty technology is expected to be commercialized with Zimmer Biomet implants in early 2027. The deal positions Zimmer Biomet to potentially become the first company to offer fully autonomous surgical robots in orthopedics.
The transaction is expected to be neutral to adjusted EPS in 2025-2027 and accretive thereafter, with revenue growth contribution beginning in 2027. The deal is anticipated to close later in 2025, subject to regulatory and shareholder approvals.
Zimmer Biomet (NYSE:ZBH) has scheduled its second quarter 2025 financial results conference call and webcast for Thursday, August 7, 2025 at 8:30 a.m. ET. The company will release its quarterly results earlier that day at 6:30 a.m. ET.
Investors can access the live audio webcast through Zimmer Biomet's Investor Relations website. For those preferring to dial in, U.S. and Canadian participants can call (888) 204-4368, while international callers should use +1 (323) 994-2093, both using conference ID 5103691.
Zimmer Biomet (NYSE: ZBH) has appointed Kevin Thornal as Group President, Global Businesses and the Americas, effective July 1, 2025. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Thornal will oversee the Americas commercial organization and lead strategy for global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units.
Thornal brings over 20 years of experience in medical technology, most recently serving as CEO of Nevro Corp. His previous roles include Group President of Global Diagnostic Solutions at Hologic, where he led double-digit growth during the COVID-19 pandemic. He also spent a decade at Stryker Corp., where he achieved sustained double-digit growth as head of North American sales for the Interventional Spine business.
Zimmer Biomet (NYSE and SIX: ZBH) announced that its management team will participate in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for Monday, June 9, 2025, at 9:20 a.m. ET. Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. The presentation will also be archived for future viewing after the conference.
Zimmer Biomet (NYSE: ZBH) reported its Q1 2025 financial results with net sales of $1.909 billion, showing a 1.1% increase year-over-year and 2.3% growth on a constant currency basis. The company posted net earnings of $182.0 million, with diluted EPS of $0.91 and adjusted EPS of $1.81.
The company updated its full-year 2025 guidance following the Paragon 28 acquisition, projecting reported revenue growth of 5.7% - 8.2% and adjusted EPS of $7.90 - $8.10. Notable highlights include strong performance in U.S. Hips driven by the Z1™ Triple-Taper Femoral Hip System and HAMMR® System, FDA clearance for Persona® Revision SoluTion™ Femur, and the completion of the Paragon 28 acquisition to strengthen their foot and ankle segment.
Geographic performance showed U.S. sales of $1.11 billion (+1.3%) and International sales of $795.5 million (+3.7% constant currency).